Himani Sharma, MD
Endocrinology, Diabetes & Metabolism · Columbus, INNPI 1811373657
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.6% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,485, 9.6 times the $156 reported in 2021.
Across 157 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$462
- Boehringer Ingelheim$354
- Amgen$290
- Insulet Corporation$230
- BETA Bionics, Inc.$219
- Sanofi-aventis U.S. LLC$202
- plus $2K from 26 others
What the payments were for
- Speaking & faculty fees$1504%
- Food & beverage$3,32894%
- Education$792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $462 |
| Boehringer Ingelheim | 12 | $354 |
| Amgen(2 entities) | 10 | $290 |
| Insulet Corporation | 11 | $230 |
| BETA Bionics, Inc. | 4 | $219 |
| Sanofi-aventis U.S. LLC | 4 | $202 |
| Corcept Therapeutics | 9 | $179 |
| Lilly USA, LLC | 10 | $164 |
| Xeris Pharmaceuticals, Inc. | 8 | $146 |
| Averitas Pharma Inc. | 6 | $134 |
| AstraZeneca(2 entities) | 7 | $130 |
| Radius Health, Inc. | 6 | $114 |
| Tandem Diabetes Care, Inc. | 6 | $94 |
| Cequr Corporation | 2 | $72 |
| Neurocrine Biosciences, Inc. | 3 | $70 |
| Medtronic | 4 | $69 |
| Soleno Therapeutics, Inc. | 3 | $62 |
| Recordati_rare_diseases_inc. | 3 | $62 |
| Ascendis Pharma Endocrinology Inc | 2 | $52 |
| Kyowa Kirin, Inc. | 2 | $52 |
| Novartis | 2 | $52 |
| Dexcom, Inc. | 3 | $52 |
| Antares Pharma, Inc. | 3 | $48 |
| AbbVie | 3 | $47 |
| Abbott | 2 | $40 |
| Ascensia Diabetes Care US Inc. | 1 | $33 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Sequel Med Tech, LLC | 1 | $29 |
| IBSA Pharma Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $20 |
| Chiasma, Inc. | 1 | $15 |
| Zealand Pharma US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,557 in reported general payments places this provider in the 60th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 280 | $386,310 |
| MounjaroTirzepatide | 182 | $330,495 |
| JardianceEmpagliflozin | 190 | $229,138 |
| TrulicityDulaglutide | 66 | $96,720 |
| FarxigaDapagliflozin Propanediol | 83 | $89,968 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $73,992 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 61 | $54,557 |
| RybelsusSemaglutide | 21 | $49,991 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 20 | $49,734 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $34,465 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $26,680 |
| VascepaIcosapent Ethyl | 53 | $22,891 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 151 | $20,470 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 105 | $20,333 |
| Novolog FlexpenInsulin Aspart | 63 | $18,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $462 | $436,300301 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $164 | $436,224310 claims |
| Boehringer IngelheimJardiance | $354 | $229,138190 claims |
| AstraZenecaFarxiga | $130 | $89,96883 claims |
| AmgenEvenity (2 Syringes) | $290 | $49,73420 claims |
| IBSA Pharma Inc.Tirosint | $21 | $6,11912 claims |
| AbbVieSynthroid | $47 | $3,56837 claims |
| Sanofi-aventis U.S. LLCLantus | $202 | $1,78113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Columbus
- Akhila RamayapallyColumbus$3K
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.